Foundation Fighting Blindness Fund Exits Major Stake in Opus Genetics

summarizeSummary

A major institutional investor, Foundation Fighting Blindness, has sold a significant portion of its holdings in Opus Genetics, reducing its stake below 5% and filing an exit amendment to its Schedule 13D.

check_boxKey Events

• Institutional Investor Exits Major Stake

  Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. have reduced their beneficial ownership in Opus Genetics below the 5% threshold.

• Significant Share Sale

  This reduction follows a $7.395 million sale of common stock on May 18, 2026, as referenced in a related Form 4 filing.

• Cessation of Reporting Obligations

  The filing indicates this will be the final amendment to their Schedule 13D, terminating their reporting obligations under Section 13(d) of the Exchange Act.

auto_awesomeAnalysis

Foundation Fighting Blindness Retinal Degeneration Fund and Foundation Fighting Blindness, Inc. have filed an amendment to their Schedule 13D, indicating they have sold shares and will cease to be a beneficial owner of more than five percent of Opus Genetics' common stock. This "exit filing" follows a $7.395 million sale reported in a recent Form 4, signaling a significant reduction in their investment and a potential loss of confidence from a key institutional investor. This divestment occurs amidst recent capital raises and an increase in authorized shares by Opus Genetics.